Table 1 Exposure comparisons by indication
Study population | Target cohorts | Target approval date | Comparator Cohorts | Comparator with earliest approval date | Comparator with latest approval date |
|---|---|---|---|---|---|
Irritable bowel diseases (Crohn’s disease or ulcerative colitis) | Remicade® | 8/24/1998 | -golimumab -certolizumab pegol -ustekinumab -vedolizumab | 4/22/2008 (certolizumab pegol) | 9/26/2016 (ustekinumab) |
Ankylosing Spondylitis | Remicade® | 12/17/2004 | -golimumab -certolizumab pegol -ixekizumab -secukinumab | 4/24/2009 (golimumab) | 8/26/2019 (ixekizumab) |
Plaque psoriasis or psoriatic arthritis | Remicade® | 5/13/2005 | -golimumab -certolizumab pegol -guselkumab -risankizumab -tildrakizumab -brodalumab -ixekizumab -secukinumab -ustekinumab | 4/24/2009 (golimumab) | 4/23/2019 (risankizumab) |
Rheumatoid arthritis | Remicade® with concurrent methotrexate* | 11/10/1999 | -certolizumab pegol -tocilizumab | 5/13/2009 (certolizumab pegol) | 1/11/2010 (tocilizumab) |